Consensus statement. Corticosteroid therapy in ENT in the context of the COVID-19 pandemic.
Anosmia
Bell's palsy
COVID-19
Prednisone
SARS-CoV-2
Sudden hearing loss
Journal
European annals of otorhinolaryngology, head and neck diseases
ISSN: 1879-730X
Titre abrégé: Eur Ann Otorhinolaryngol Head Neck Dis
Pays: France
ID NLM: 101531465
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
pubmed:
3
6
2020
medline:
12
9
2020
entrez:
3
6
2020
Statut:
ppublish
Résumé
This consensus statement about the indications and modalities of corticosteroid treatment in the context of the COVID-19 pandemic was jointly written by experts from the French Association of Otology and Oto-Neurology (AFON) and from the French Society of Otorhinolaryngology, Head and Neck Surgery (SFORL). There is currently not enough data in favour of danger or benefit from corticosteroids in COVID-19, so until this matter is resolved it is advisable to limit their indications to the most serious clinical pictures for which it is well established that this type of treatment has a positive impact on the progression of symptoms. In Grade V and VI Bell's palsy according to the House-Brackmann grading system, a week's course of oral corticosteroids is recommended. Corticosteroid therapy is also recommended in cases of sudden hearing loss of more than 60dB, either in the form of intratympanic injections or a week's course of oral medication. In rhinology, there is no indication for systemic corticosteroid therapy in the current situation. However, patients are advised to continue with their local corticosteroid therapy in the form of a nasal spray or by inhalation. Treatments with corticosteroid nasal sprays can still be prescribed if there is no alternative. Finally, systemic or local corticosteroid therapy is not indicated for bacterial ENT infections.
Identifiants
pubmed: 32482571
pii: S1879-7296(20)30104-6
doi: 10.1016/j.anorl.2020.04.014
pmc: PMC7198134
pii:
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Types de publication
Consensus Development Conference
Journal Article
Practice Guideline
Langues
eng
Sous-ensembles de citation
IM
Pagination
315-317Informations de copyright
Copyright © 2020 Elsevier Masson SAS. All rights reserved.
Références
ACS Chem Neurosci. 2020 May 6;11(9):1200-1203
pubmed: 32283006
Eur Arch Otorhinolaryngol. 2020 Aug;277(8):2251-2261
pubmed: 32253535
Eur Ann Otorhinolaryngol Head Neck Dis. 2020 Sep;137(4):303-308
pubmed: 32419879
Radiology. 2020 Aug;296(2):E32-E40
pubmed: 32101510
Lancet Infect Dis. 2020 Sep;20(9):1015-1016
pubmed: 32304629
Eur Ann Otorhinolaryngol Head Neck Dis. 2020 Sep;137(4):309-314
pubmed: 32387072
JAMA Otolaryngol Head Neck Surg. 2020 Jul 1;146(7):674-675
pubmed: 32267483
J Otol. 2017 Sep;12(3):117-124
pubmed: 29937846
Cochrane Database Syst Rev. 2019 Sep 05;9:CD001869
pubmed: 31486071
Curr Opin Otolaryngol Head Neck Surg. 2004 Oct;12(5):378-83
pubmed: 15377947
Eur Ann Otorhinolaryngol Head Neck Dis. 2018 Feb;135(1S):S29-S32
pubmed: 29338942
Cochrane Database Syst Rev. 2016 Jul 18;7:CD001942
pubmed: 27428352
Otolaryngol Head Neck Surg. 2001 Nov;125(5):537-43
pubmed: 11700457
Acta Otolaryngol. 2017 Jun;137(6):598-605
pubmed: 27921520